Macrogenics Inc
NASDAQ:MGNX
Products, Regulatory, Earnings Announcements
MacroGenics Announces Survival Results From Study Of Margenza In Patients With Her2-Positive Metastatic Breast Cancer
Published: 09/07/2021 21:15 GMT
Macrogenics Inc (MGNX) - Macrogenics Announces Final Overall Survival Results From Sophia Study of Margenza™ in Patients With Her2-positive Metastatic Breast Cancer.
Macrogenics - Final Overall Survival Analysis Did Not Demonstrate a Statistically Significant Advantage for Margenza Over Trastuzumab.
Macrogenics Inc - Safety Profile Remains Similar to What Has Been Reported Previously.
Macrogenics - Adverse Reactions in Greater Than 20% of Patients With Margenza With Chemotherapy Were Consistent With Existing Product Label.
Macrogenics - Final Overall Survival Analysis Did Not Demonstrate a Statistically Significant Advantage for Margenza Over Trastuzumab.
Macrogenics Inc - Safety Profile Remains Similar to What Has Been Reported Previously.
Macrogenics - Adverse Reactions in Greater Than 20% of Patients With Margenza With Chemotherapy Were Consistent With Existing Product Label.
Revenue is expected to be $37.12 Million
Adjusted EPS is expected to be -$0.68
Next Quarter Revenue Guidance is expected to be $35.08 Million
Next Quarter EPS Guidance is expected to be -$0.71
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.68
Next Quarter Revenue Guidance is expected to be $35.08 Million
Next Quarter EPS Guidance is expected to be -$0.71
More details on our Analysts Page.